Regulation and Function of the PD-L1 Checkpoint

177Citations
Citations of this article
464Readers
Mendeley users who have this article in their library.

Abstract

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus expression of PD-L1 on tumor cells and other cells in the tumor microenviroment is of major clinical relevance. Here we review the roles of the PD-1-PD-L1 axis in cancer, focusing on recent findings on the mechanisms that regulate PD-L1 expression at the transcriptional, posttranscriptional, and protein level. We place this knowledge in the context of observations in the clinic and discuss how it may inform the design of more precise and effective cancer immune checkpoint therapies. Schumacher et al. review the mechanisms that control PD-L1 expression in cancer and discuss how the growing understanding of the regulation and function of the PD-1-PD-L1 axis can guide more precise and effective immune checkpoint therapies.

Cite

CITATION STYLE

APA

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018, March 20). Regulation and Function of the PD-L1 Checkpoint. Immunity. Cell Press. https://doi.org/10.1016/j.immuni.2018.03.014

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free